⌘K
t
| Date | 8 Mar 2023 |
| Time | 08:30:02 |
| Category | Director/PDMR dealings |
| ID | 2733S |
Hong Kong, Shanghai & Florham Park, NJ - Wednesday, March 8, 2023: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; SEHK:13) has received notifications that Mr Johnny Cheng, Executive Director and Chief Financial Officer, sold a total of 1,300,000 Ordinary Shares of US$0.10 each of the Company at an average price of HK$27.073 per Ordinary Shares on March 3, 2023 and March 6, 2023.
Following the above sale of 1,300,000 Ordinary Shares, the holding of Mr Cheng is 1,261,460 Ordinary Shares and 274,493 ADSs Note, representing approximately 0.3% of the current issued share capital of the Company.
Note: 274,493 ADSs included (i) 41,552 ADSs currently held by Mr Cheng, (ii) 217,800 ADSs granted under Share Option Scheme and (iii) 15,141 ADSs as beneficiary of a trust under long term incentive plan.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||||
|
a) |
Name |
Mr Johnny Cheng
|
|||||||
|
2 |
Reason for the notification |
||||||||
|
a) |
Position/status |
Executive Director and Chief Financial Officer
|
|||||||
|
b) |
Initial notification/Amendment
|
Initial notification
|
|||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||
|
a) |
Name
|
HUTCHMED (China) Limited |
|||||||
|
b)
|
LEI |
2138006X34YDQ6OBYE79 |
|||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||
|
a) |
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of US$0.10 each
DI ISIN: KYG4672N1198 |
|||||||
|
b) |
Nature of the transaction
|
Sale of 830,000 Ordinary Shares on March 3, 2023 at an average price of HK$27.101.
|
|||||||
|
c) |
Price(s) and volume(s) |
|
|
|
|
||||
|
|
Price(s) |
Volume(s) |
|
||||||
|
|
HK$26.850 |
50,000 Ordinary Shares |
|
||||||
|
|
HK$26.950 |
20,000 Ordinary Shares |
|
||||||
|
|
HK$27.000 |
110,000 Ordinary Shares |
|
||||||
|
|
HK$27.005 |
50,000 Ordinary Shares |
|
||||||
|
|
HK$27.015 |
20,000 Ordinary Shares |
|
||||||
|
|
HK$27.016 |
40,000 Ordinary Shares |
|
||||||
|
|
HK$27.027 |
30,000 Ordinary Shares |
|
||||||
|
|
HK$27.050 |
10,000 Ordinary Shares |
|
||||||
|
|
HK$27.091 |
200,000 Ordinary Shares |
|
||||||
|
|
HK$27.100 |
50,000 Ordinary Shares |
|
||||||
|
|
HK$27.113 |
100,000 Ordinary Shares |
|
||||||
|
|
HK$27.150 |
20,000 Ordinary Shares |
|
||||||
|
|
HK$27.200 |
30,000 Ordinary Shares |
|
||||||
|
|
HK$27.300 |
40,000 Ordinary Shares |
|
||||||
|
|
HK$27.450 |
10,000 Ordinary Shares |
|
||||||
|
|
HK$27.500 |
20,000 Ordinary Shares |
|
||||||
|
|
HK$27.656 |
20,000 Ordinary Shares |
|
||||||
|
|
HK$27.700 |
10,000 Ordinary Shares |
|
||||||
|
|
|
|
|
||||||
|
d) |
Aggregated information
|
Aggregated volume: 830,000 Ordinary Shares Price information: HK$22,494,120 |
|||||||
|
e) |
Date of the transaction |
2023-03-03
|
|||||||
|
f) |
Place of the transaction |
Hong Kong Stock Exchange
|
|||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||
|
a) |
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of US$0.10 each
DI ISIN: KYG4672N1198 |
|||||||
|
b) |
Nature of the transaction
|
Sale of 470,000 Ordinary Shares on March 6, 2023 at an average price of HK$27.022.
|
|||||||
|
c) |
Price(s) and volume(s) |
|
|
|
|
||||
|
|
Price(s) |
Volume(s) |
|
||||||
|
|
HK$26.850 |
30,000 Ordinary Shares |
|
||||||
|
|
HK$26.900 |
10,000 Ordinary Shares |
|
||||||
|
|
HK$26.908 |
10,000 Ordinary Shares |
|
||||||
|
|
HK$26.950 |
70,000 Ordinary Shares |
|
||||||
|
|
HK$27.000 |
50,000 Ordinary Shares |
|
||||||
|
|
HK$27.050 |
68,500 Ordinary Shares |
|
||||||
|
|
HK$27.060 |
200,000 Ordinary Shares |
|
||||||
|
|
HK$27.100 |
20,000 Ordinary Shares |
|
||||||
|
|
HK$27.250 |
10,000 Ordinary Shares |
|
||||||
|
|
HK$27.300 |
1,500 Ordinary Shares |
|
||||||
|
|
|
|
|
||||||
|
d) |
Aggregated information
|
Aggregated volume: 470,000 Ordinary Shares Price information: HK$12,700,455 |
|||||||
|
e) |
Date of the transaction |
2023-03-06
|
|||||||
|
f) |
Place of the transaction |
Hong Kong Stock Exchange
|
|||||||
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception, HUTCHMED has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.
Investor Enquiries |
|
|
Mark Lee, Senior Vice President |
+852 2121 8200 |
|
Annie Cheng, Vice President |
+1 (973) 306 4490 |
|
|
|
Media Enquiries |
|
|
Americas - Brad Miles, Solebury Trout |
+1 (917) 570 7340 (Mobile) |
|
Europe - Ben Atwell / Alex Shaw, FTI Consulting |
+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
|
Asia - Zhou Yi, Brunswick |
+852 9783 6894 (Mobile) |
|
|
|
Nominated Advisor |
|
|
Atholl Tweedie / Freddy Crossley, |
+44 (20) 7886 2500 |